Omeros Corporation

October is not a lucky month for Omeros Corporation . Two years ago, narsoplimab was kicked back by the US Food and Drug Administration in its lead indication of stem cell transplant-associated throm

That Novartis AG ’s IgA nephropathy (IgAN) candidate iptacopan hit on proteinuria in its Phase III trial is good news, as far as it goes, but that is not very far. Without the extent of the product’s

Major amendments containing new clinical trial data or analyses are driving the high usage of three-month extensions to PDUFA goal dates over the past year, an analysis of the Pink Sheet ’s US FDA Pe

The failure of Silicon Valley Bank, the largest bank failure since Washington Mutual collapsed in 2008, has raised concerns among investors about potential contagion, but also about the significant ex